ScinoPharm Taiwan, Ltd. (TPE:1789)

Market Cap	19.49B +11.0%
Revenue (ttm)	3.19B -8.6%
Net Income	193.01M -51.7%
EPS	0.24 -52.4%
Shares Out	790.74M
PE Ratio	102.63
Forward PE	64.87
Dividend	0.35 (1.42%)
Ex-Dividend Date	Jul 3, 2025

Volume	3,286,818
Average Volume	4,117,404
Open	25.00
Previous Close	24.65
Day's Range	23.30 - 25.25
52-Week Range	16.25 - 29.10
Beta	0.30
RSI	56.56
Earnings Date	Feb 26, 2026

About ScinoPharm Taiwan

ScinoPharm Taiwan, Ltd., together with its subsidiaries, research and develops, produces, and sells active pharmaceutical ingredients (API) to pharmaceutical companies in Taiwan, rest of Asia, Europe, the America, and internationally. The company provides small molecular drugs, protein drugs, complex natural molecules and derivatives, synthesis services for biochemistry molecules, such as peptides and nucleic acids; generic API manufacturing services; outsourcing services. It offers CDMO services, such as contract analytical testing services, s...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1997
• Employees: 540
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 1789

Financial Performance

In 2024, ScinoPharm Taiwan's revenue was 3.41 billion, an increase of 6.91% compared to the previous year's 3.19 billion. Earnings were 339.35 million, an increase of 18.22%.